<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>慢性阻塞性肺病 &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/manxingzusaixingfeibing/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Tue, 26 Oct 2021 06:49:29 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>慢性阻塞性肺病 &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>2021-2025年中国沙特美罗替卡松市场研究报告：在2016-2020的CAGR大约为-3.8%</title>
		<link>https://www.yuanzhezixun.com/criyuanzhe2021-2025nianzhongguoshatemeiluotikasongshichangyanjiubaogao/</link>
		
		<dc:creator><![CDATA[Timlee]]></dc:creator>
		<pubDate>Tue, 11 May 2021 07:20:17 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[COPD]]></category>
		<category><![CDATA[Glaxo Wellcome]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[SERETIDE]]></category>
		<category><![CDATA[Wellcome Foundation]]></category>
		<category><![CDATA[可逆性阻塞性气道疾病]]></category>
		<category><![CDATA[哮喘]]></category>
		<category><![CDATA[慢性阻塞性肺病]]></category>
		<category><![CDATA[沙特美罗替卡松]]></category>
		<category><![CDATA[沙特美罗替卡松区域分析]]></category>
		<category><![CDATA[沙特美罗替卡松市场份额]]></category>
		<category><![CDATA[沙特美罗替卡松市场竞争]]></category>
		<category><![CDATA[沙特美罗替卡松市场细分]]></category>
		<category><![CDATA[沙特美罗替卡松市场规模]]></category>
		<category><![CDATA[润生药业]]></category>
		<category><![CDATA[舒利迭]]></category>
		<category><![CDATA[葛兰素史克]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=24015</guid>

					<description><![CDATA[沙特美罗替卡松是一种用于慢性阻塞性肺病（COPD）和可逆性阻塞性气道疾病（包括哮喘）的规律治疗,由葛兰素史克公司研发。CRI元哲的调研数据显示，2016-2019年，沙特美罗替卡松在中国市场的销售额呈上升趋势。2020年销售额约为3亿元，相较于2019年下降了大约21.6%。主要原因是COVID-19疫情使医院整体诊疗业务受到冲击。沙特美罗替卡松在2016-2020的CAGR大约为-3.8%。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
